Blood-brain barrier in drug discovery : (Record no. 65215)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07385cam a2200841 i 4500 |
| 001 - CONTROL NUMBER | |
| control field | sulb-eb0033563 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | BD-SySUS |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20170713221410.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr ||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 141017t20152015nju ob 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER | |
| LC control number | 2014041569 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | DLC |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | DLC |
| Modifying agency | N$T |
| -- | DG1 |
| -- | YDXCP |
| -- | E7B |
| -- | UWO |
| -- | COO |
| -- | CDX |
| -- | OCLCQ |
| -- | OCLCO |
| -- | MMU |
| -- | DEBBG |
| -- | LOA |
| -- | KSU |
| -- | BD-SySUS |
| 019 ## - | |
| -- | 904539318 |
| -- | 960204304 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118788493 |
| Qualifying information | (ePub) |
| International Standard Book Number | 1118788494 |
| Qualifying information | (ePub) |
| International Standard Book Number | 9781118788547 |
| Qualifying information | (Adobe PDF) |
| International Standard Book Number | 1118788540 |
| Qualifying information | (Adobe PDF) |
| International Standard Book Number | 9781118788523 |
| Qualifying information | (ebook) |
| International Standard Book Number | 1118788524 |
| Qualifying information | (ebook) |
| International Standard Book Number | 9781322572406 |
| Qualifying information | (ebook) |
| International Standard Book Number | 1322572402 |
| Qualifying information | (ebook) |
| Canceled/invalid ISBN | 9781118788356 |
| Qualifying information | (hardback) |
| Canceled/invalid ISBN | 1118788354 |
| Qualifying information | (hardback) |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | CHDSB |
| System control number | 006372535 |
| OCLC library identifier | CHVBK |
| System control number | 333017153 |
| OCLC library identifier | DEBBG |
| System control number | BV042795864 |
| OCLC library identifier | GBVCP |
| System control number | 819918776 |
| OCLC library identifier | DEBBG |
| System control number | BV043397214 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)893389733 |
| Canceled/invalid control number | (OCoLC)904539318 |
| -- | (OCoLC)960204304 |
| 037 ## - SOURCE OF ACQUISITION | |
| Stock number | 688522 |
| Source of stock number/acquisition | MIL |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | pcc |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM315 |
| 060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | WL 200 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 071000 |
| Source | bisacsh |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.7/8 |
| Edition number | 23 |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | MAIN |
| 245 00 - TITLE STATEMENT | |
| Title | Blood-brain barrier in drug discovery : |
| Remainder of title | optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs / |
| Statement of responsibility, etc. | edited by Li Di, Edward H. Kerns. |
| 246 30 - VARYING FORM OF TITLE | |
| Title proper/short title | Optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Hoboken, New Jersey : |
| Name of producer, publisher, distributor, manufacturer | Wiley, |
| Date of production, publication, distribution, manufacture, or copyright notice | [2015] |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2015 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (xiv, 586 pages, 4 unnumbered pages of plates) : |
| Other physical details | illustrations (some color) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| Content type term | still image |
| Content type code | sti |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc | Includes bibliographical references and index. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on online resource; title from PDF title page (ebrary, viewed May 9, 2016). |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Introduction and overview / Li Di, and Edward H. Kerns -- Part 1: Pharmacokinetics of brain exposure. Pharmacokinetics of CNS penetration / Andreas Reichel -- Free drug hypothesis for CNS drug candidates / Xingrong Liu and Cuiping Chen -- Species differences and impact of disease state on BBB / Jean-Marie Nicolas -- Part 2: Mechanisms of drugs across the blood-brain barrier. Passive diffusion permeability of the BBB: examples and SAR / Scott Summerfield, Phil Jeffrey, Jasminder Sahi, and Liangfu Chen -- Efflux transport at the BBB: examples and SAR / Jerome Hochman -- Establishment of P-glycoprotein structure-transport relationships to optimize CNS exposure in drug discovery / Jerome H. Hochman, Sookhee N. Ha, and Robert P. Sheridan -- Uptake transport at the BBB: examples and SAR / Ziquiang Cheng and Qian Liu -- Transport of protein and antibody therapeutics across the blood-brain barrier / William M. Pardridge -- Part 3: Predicting and measuring brain exposure of drugs. In silico tools for assessing brain exposure / Hongming Chen, Susanne Winiwarter, and Ola Engkvist -- In vitro assays for assessing BBB permeability: vascular cells, artificial membranes, brain slice, cell uptake / Alex Avdeef, Mária A. Deli, and Winfried Neuhaus -- Human-based in vitro endothelial cell models / Hannah K. Wilson and Eric Shusta -- Methods for assessing brain binding / Li Di and Cheng Chang -- In vivo studies of brain exposure in drug discovery / Edward H. Kerns -- PBPK modelling approach for predictions of human CNS drug brain distribution / Elizabeth C.M. de Lange -- PK/PD modeling of CNS drug candidates / Johan Gabrielsson, Stephan Hjorth, and Lambertus A. Peletier -- Microdialysis to assess free drug concentration in brain / William Kielbasa and Robert E. Stratford, Jr. -- Imaging techniques for central nervous system (CNS) drug discovery / Lei Zhang and Anabella Villalobos -- Part 4: Modulating brain penetration of leads during drug discovery. Designing CNS drugs for optimal brain exposure / Zoran Rankovic -- Case studies of CNS drug optimization: medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts -- Designing peripheral drugs for minimal brain exposure / Peter Bungay, Sharan Bagal, and Andy Pike -- Case studies of non-CNS drugs to minimize brain penetration: nonsedative antihistamines / Andrew Crowe -- Part 5: Case studies in CNS drug discovery. Case study 1: the discovery and development of perampanel / Antonio Laurenza, Jim Ferry, Haichen Yang, Shigeki Hibi, Takahisa Hanada, and Andrew Satlin -- Case study 2: the discovery and development of the multimodal acting antidepressant vortioxetine / Christoffer Bundgaard, Alan L. Pehrson, Connie Sánchez, and Benny Bang-Andersen -- Part 6: Drug delivery techniques to CNS. Brain delivery using nanotechnology / Huile Gao and Xinguo Jiang -- Intranasal delivery to the central nervous system / Lisbeth Illum -- Part 7: Future prospects in blood-brain barrier understanding and drug discovery. Future perspectives / N. Joan Abbott . |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Blood-brain barrier |
| General subdivision | Metabolism. |
| Topical term or geographic name as entry element | Drug development. |
| Topical term or geographic name as entry element | MEDICAL |
| General subdivision | Pharmacology. |
| Source of heading or term | bisacsh |
| Topical term or geographic name as entry element | Blood-Brain Barrier |
| General subdivision | metabolism. |
| Topical term or geographic name as entry element | Central Nervous System Agents |
| General subdivision | pharmacokinetics. |
| Topical term or geographic name as entry element | Blood-Brain Barrier |
| General subdivision | drug effects. |
| Topical term or geographic name as entry element | Central Nervous System Diseases |
| General subdivision | drug therapy. |
| Topical term or geographic name as entry element | Drug Discovery |
| General subdivision | methods. |
| Topical term or geographic name as entry element | Drug-Related Side Effects and Adverse Reactions |
| General subdivision | prevention & control. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Di, Li, |
| Relator term | editor. |
| Personal name | Kerns, Edward Harvel, |
| Relator term | editor. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Title | Blood-brain barrier in drug discovery. |
| Place, publisher, and date of publication | Hoboken, New Jersey : John Wiley & Sons Inc., [2015] |
| International Standard Book Number | 9781118788356 |
| Record control number | (DLC) 2014040935 |
| -- | (OCoLC)889736023 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://onlinelibrary.wiley.com/book/10.1002/9781118788523">http://onlinelibrary.wiley.com/book/10.1002/9781118788523</a> |
| Public note | Wiley Online Library [Free Download only for SUST IP] |
| 938 ## - | |
| -- | Coutts Information Services |
| -- | COUT |
| -- | 30543041 |
| -- | ebrary |
| -- | EBRY |
| -- | ebr11005763 |
| -- | EBSCOhost |
| -- | EBSC |
| -- | 935074 |
| -- | YBP Library Services |
| -- | YANK |
| -- | 11225833 |
| -- | YBP Library Services |
| -- | YANK |
| -- | 12229907 |
| -- | YBP Library Services |
| -- | YANK |
| -- | 12888483 |
| 994 ## - | |
| -- | 92 |
| -- | DG1 |
No items available.